Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Dermatologic 1

Conditions

Sarcoma 1Neoplasms, Germ Cell and Embryonal 1Melanoma 1Castration Resistant Prostate Cancer 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Radiotherapy 5Gemcitabine 4Cyclophosphamide 4pazopanib 3Docetaxel 3Biopsy 3pembrolizumab 2olaparib 2liposomal doxorubicin 2Vincristine 2Trastuzumab 2Trabectedin 2Temozolomide 2Taxes 2Surgical Procedures, Operative 2Specimen Handling 2Proton Therapy 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ifosfamide 2Filgrastim 2Etoposide 2Drug Therapy 2Doxorubicin 2Celecoxib 2Carboplatin 2Ascorbic Acid 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2trastuzumab biosimilar HLX02 1tozuleristide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Sarcoma × bintrafusp alfa protein, human × Clear all
NCT04648826 2021-12-17

Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
DermatologicGenitourinarySarcoma

Carcinoma, Renal Cell, Melanoma, Neoplasms, Germ Cell and Embryonal, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡